Skip to main content
TipRanks
Go Ultimate75% OFF

ChronoScale (23E1) AI Stock Analysis

1 Followers
DE:23E1

ChronoScale

(Frankfurt:23E1)

Rating:―N/A
Action:N/A
Date:―

No summary available

Positive Factors
Exceptional Revenue GrowthRevenue expansion of roughly 341% demonstrates strong recent demand and materially increases the potential scale of the business. Maintaining gross margin near 53% during this growth suggests the offering has reasonable unit economics, although continued execution is needed to convert scale into profits.
Negative Factors
Deepening Operating LossesThe company has not yet demonstrated operating leverage: rapid revenue growth is being outweighed by a cost structure that produces materially larger losses. Persistent negative profitability can consume capital, limit reinvestment capacity, and weaken the durability of the growth model.

ChronoScale (23E1) vs. iShares MSCI Germany ETF (EWG)

-100%0%100%200%300%400%500%600%700%DE:23E1+159.73%EWG+7.58%Dec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
Market Cap
EUR 33.46M
Dividend Yield
―
Average Volume (3M)
4
Price to Earnings (P/E)
―
Beta (1Y)
1.92
Revenue Growth
170.45%
EPS Growth
53.55%
Country
Germany
Employees
86
Sector
Technology
Sector Strength
61
Industry
Information Technology Services

ChronoScale Business Overview & Revenue Model

Company Description

ChronoScale Corporation designs and develops a compute platform to support artificial intelligence (AI) workloads. The company focuses on large-scale deployments and provides dedicated compute environments engineered for performance, consistency, and...

ChronoScale Earnings Call Summary

Earnings Call Date:Jul 28, 2025(Q2-2025)|% Change Since:159.73%|Next Earnings Date:Aug 03, 2026
Earnings Call SentimentNegative

The earnings call highlighted significant challenges, including a major decline in revenue and gross margin, alongside an increased net loss. Despite these challenges, there were positive developments in the personal health segment, strategic partnerships, and AI initiatives. However, the financial setbacks appear to overshadow the positive developments.

Positive Updates

Growth in Personal Health Segment
Personal Health product revenues grew by more than 50% year-over-year in the first half of 2025, driven by the Ekso Indego Personal device.

Negative Updates

Significant Revenue Decline
Second quarter 2025 revenue of $2.1 million was significantly lower compared to $5 million in the second quarter of 2024, due to delays in Enterprise Health sales.

Company Guidance

During the Ekso Bionics Second Quarter 2025 Financial Results Conference Call, the company reported a disappointing revenue of $2.1 million, a significant drop from $5 million in the same quarter of 2024, primarily due to short-term delays in completing multi-device Enterprise Health sales. Despite this decline, Ekso Indego Personal device sales partially offset the loss. Gross profit for Q2 2025 was $800,000, with a gross margin of approximately 40%, down from a gross profit of $2.6 million and a gross margin of 53% in Q2 2024. Operating expenses were reduced by 4% to $4.8 million. The net loss applicable to common stockholders increased to $2.7 million or $1.24 per share, from $2.4 million or $1.99 per share in the previous year. The company held $5.2 million in cash and restricted cash as of June 30, 2025. Ekso remains optimistic about closing deferred sales and expects Personal Health product revenues to grow significantly, having already increased by over 50% in the first half of 2025 compared to the previous year.

ChronoScale Risk Analysis

ChronoScale disclosed 60 risk factors in its most recent earnings report. ChronoScale reported the most risks in the "Finance & Corporate" category.

Higher RiskSector Avg.Lower RiskFinance & CorporateTech & InnovationLegal & RegulatoryProductionAbility to SellMacro & Political
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy

Latest Risks Added

3 New Risks
1.We are a "controlled company" under Nasdaq's corporate governance rules and, as a result, qualify for, and rely on, exemptions from certain corporate governance requirements. As a result, investors in the Company do not have the same protections afforded to stockholders of companies that are subject to such requirements.Q2, 2026
2.We are currently a "smaller reporting company" and the reduced reporting requirements applicable to such companies may make our common stock less attractive to investors.Q2, 2026
3.Provisions in our Articles (as defined below), our Bylaws (as defined below), and Nevada law may discourage a takeover attempt even if a takeover might be beneficial to our stockholders.Q2, 2026

ChronoScale Peers Comparison

Overall Rating

UnderperformOutperform
Sector (61)

Financial Indicators

DE:23E1 against its peers
NameOverall RatingMarket CapP/E RatioROEDividend YieldRevenue GrowthEPS Growth
Sector *61Neutral$37.18B12.37-10.20%1.83%8.50%-7.62%
HBIOHBIO52Neutral$40.75M-3.47-130.06%―2.34%78.52%
MLSSMLSS44Neutral$26.64M-7.03-122.29%―3.93%48.18%
LUCYLUCY42Neutral$6.81M-0.63-102.66%―56.89%52.61%

* Technology Sector Average

Performance Comparison

0%200%400%600%DE:23E1HBIOMLSSLUCYDec '25Jan '26Feb '26Mar '26Apr '26May '26Jun '26Jul '26Aug '26Sep '26Oct '26Nov '26
DE:23E1 and its peers over the selected period
Show on chartTickerCompany NamePriceChange% Change
DE:23E1Chronoscale Corporation8.615.29159.73%
HBIOHarvard Bioscience9.082.8846.52%
MLSSMilestone Scientific Inc0.28-0.04-13.44%
LUCYInnovative Eyewear, Inc.0.77-0.83-51.75%
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.

Disclaimer

This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.